1. Search Result
Search Result
Results for "

Ulcerative colitis model

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7635

    β-D-Glucopyranosyl oleanolate

    NO Synthase COX Interleukin Related Claudin p38 MAPK Akt PI3K Inflammation/Immunology
    Oleanolic acid 28-O-β-D-glucopyranoside (β-D-Glucopyranosyl oleanolate) is an orally active pentacyclic triterpenoid compound. Oleanolic acid 28-O-β-D-glucopyranoside has anti-inflammatory effects. In ulcerative colitis models, Oleanolic acid 28-O-β-D-glucopyranoside can inhibit the inflammatory response, enhance the intestinal epithelial barrier function, and modulate the gut microbiota. Its mechanism of action is related to the PI3K-AKT and MAPK signaling pathways. Oleanolic acid 28-O-β-D-glucopyranoside can be used in the research of diseases such as colitis .
    Oleanolic acid 28-O-β-D-glucopyranoside
  • HY-114360A
    Taurohyodeoxycholic acid sodium
    1 Publications Verification

    Interleukin Related TNF Receptor Inflammation/Immunology
    Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.
    Taurohyodeoxycholic acid sodium
  • HY-P99439

    IMA-638

    Interleukin Related Inflammation/Immunology
    Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
    Anrukinzumab
  • HY-114360AS1

    Isotope-Labeled Compounds TNF Receptor Interleukin Related Inflammation/Immunology
    Taurohyodeoxycholic acid-d4 (sodium) is a deuterated labeled Taurohyodeoxycholic acid (sodium) . Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.
    Taurohyodeoxycholic acid-d4 sodium
  • HY-151252

    Proteasome NOD-like Receptor (NLR) Inflammation/Immunology
    NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β .
    NIC-0102
  • HY-107648
    McN-A-343
    2 Publications Verification

    mAChR Inflammation/Immunology
    McN-A-343 is a selective M1 muscarinic agonist that stimulates muscarinic transmission in sympathetic ganglia. McN-A-343 reduces inflammation and oxidative stress in an experimental model of ulcerative colitis . McN-A-343 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    McN-A-343
  • HY-D1377

    Fluorescent Dye Others
    Citrulline-specific probe-rhodamine hydrate is a specific probe for citrulline (Citrulline) combined with a rhodamine fluorescent group. Citrulline is the hydrolysis product of arginine catalyzed by protein arginine deiminase (PAD). PAD is abnormally activated in many diseases, leading to increased citrulline levels. Citrulline-specific probe-rhodamine hydrate is a biological probe that can identify diseases showing abnormal increases in PAD activity and may be effectively used in animal models of ulcerative colitis .
    Citrulline-specific probe-rhodamine hydrate
  • HY-145829

    JAK Apoptosis Inflammation/Immunology
    Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis .
    Tofacitinib Prodrug-1
  • HY-172208

    PROTACs Cyclic GMP-AMP Synthase Inflammation/Immunology
    PROTAC cGAS degrader-1 (Compound TH35) is an effective and selective cGAS PROTAC degrader, with DC50 values of 0.9 μM and 4.6 μM in THP-1 and RAW 264.7 cells, respectively. PROTAC cGAS degrader-1 can inhibit the activation of cGAS signaling induced by dsDNA. PROTAC cGAS degrader-1 has anti-inflammatory activity and can be used in the research of cGAS-related inflammatory diseases. (Pink: cGAS inhibitor (HY-133916); Black: Linker (HY-W411604); Blue: E3 ligase ligand (HY-43722))
    PROTAC cGAS degrader-1
  • HY-143678

    Biochemical Assay Reagents Others
    Citrulline-specific probe-biotin is a biotinylated probe for detection of citrulline. Citrulline is the hydrolysis product of arginine catalyzed by protein arginine deiminase (PAD). PAD is abnormally activated in many diseases, leading to increased citrulline levels. Citrulline-specific probe-biotin is a biological probe that can identify diseases showing abnormal increases in PAD activity and may be effectively used in animal models of ulcerative colitis .
    Citrulline-specific probe-biotin
  • HY-172406

    p38 MAPK Interleukin Related IRAK Inflammation/Immunology
    MAPK-IN-4 (Compound c1) is an orally active anti-inflammatory agent. MAPK-IN-4 can inhibit the expression and release of pro-inflammatory cytokines IL-6 and TNF-α induced by LPS (HY-D1056). MAPK-IN-4 can bind to IRAK4 and exert its anti-inflammatory effect by inhibiting the MAPK pathway .
    MAPK-IN-4
  • HY-173129

    NF-κB Toll-like Receptor (TLR) Inflammation/Immunology
    Anti-inflammatory agent 97 (Compound 1l), an anti-inflammation agent, can also inhibit oxidative stress. Anti-inflammatory agent 97 can inhibit the colonic shortening and suppress inflammatory symptoms of the colonic tissue in the DSS (HY-116282C)-induced ulcerative colitis mice model. Anti-inflammatory agent 97 can regulate the inflammation-related TLR4/NF-κB signaling pathway and the oxidative stress-related Nrf2/HO-1 signaling pathway .
    Anti-inflammatory agent 97
  • HY-162641

    IRAK NF-κB p38 MAPK TNF Receptor Inflammation/Immunology
    AF-45 inhibits IRAK4 and IRAK1, with IC50s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-α in macrophages, with IC50s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for NF-κB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models .
    AF-45

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: